These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Biocompatible implants for the sustained zero-order release of narcotic antagonists. Abrahams RA; Ronel SH J Biomed Mater Res; 1975 May; 9(3):355-66. PubMed ID: 1176491 [TBL] [Abstract][Full Text] [Related]
8. Chromatographic detection of narcotic antagonists in human urine. Digregorio GJ; O'Brien J Chromatogr; 1974 Dec; 101(2):424-7. PubMed ID: 4443404 [No Abstract] [Full Text] [Related]
9. Sustained administration of cyclazocine for antagonism of morphine. Sullivan MF; Ruemmler PS; Kalkwarf DR Drug Alcohol Depend; 1976 Oct; 1(6):415-28. PubMed ID: 1035154 [TBL] [Abstract][Full Text] [Related]
10. Development of Chronomers tm for narcotic antagonists. Capozza RC; Schmitt EE; Seńdelbeck LR Natl Inst Drug Abuse Res Monogr Ser; 1976 Jan; (4):39-42. PubMed ID: 967234 [TBL] [Abstract][Full Text] [Related]
11. Chronic effects of select narcotic antagonists in mice. Nuite JA; Harris LS Adv Biochem Psychopharmacol; 1973; 8(0):417-25. PubMed ID: 4794888 [No Abstract] [Full Text] [Related]
12. The metabolic fate of H3-cyclazocine in dogs. Mulé SJ; Clements TH; Gorodetzky CW J Pharmacol Exp Ther; 1968 Apr; 160(2):387-96. PubMed ID: 5239862 [No Abstract] [Full Text] [Related]
13. Studies of EN-1639A (naltrexone): a new narcotic antagonist. Resnick RB; Volavka J; Freedman AM; Thomas M Am J Psychiatry; 1974 Jun; 131(6):646-50. PubMed ID: 4827793 [No Abstract] [Full Text] [Related]
14. [Withdrawal programmes for narcotics addicts in the USA]. Neudek K Munch Med Wochenschr; 1970 May; 112(22):1054-6. PubMed ID: 4987316 [No Abstract] [Full Text] [Related]
15. Clinical studies of cyclazocine in the treatment of narcotic addiction. Freedman AM; Fink M; Sharoff R; Zaks A Am J Psychiatry; 1968 May; 124(11):1499-504. PubMed ID: 4869436 [No Abstract] [Full Text] [Related]
16. Development of injectable microcapsules for use in the treatment of narcotic addiction. Thies C Natl Inst Drug Abuse Res Monogr Ser; 1976 Jan; (4):19-20. PubMed ID: 967230 [TBL] [Abstract][Full Text] [Related]
17. Behavioral and morphine-antagonist effects of the optical isomers of pentazocine and cyclazocine. McMillan DE; Harris LS J Pharmacol Exp Ther; 1972 Mar; 180(3):269-79. PubMed ID: 5012778 [No Abstract] [Full Text] [Related]
18. Use of synthetic polypeptides in the preparation of biodegradable delivery vehicles for narcotic antagonists. Sidman KR; Arnold DL; Steber WD; Nelsen L; Granchelli FE; Strong P; Sheth SG Natl Inst Drug Abuse Res Monogr Ser; 1976 Jan; (4):33-8. PubMed ID: 967233 [TBL] [Abstract][Full Text] [Related]
19. [EFFECT OF DOSAGE FORMS ON THE RESORPTION OF DRUGS]. FINHOLT P Sven Farm Tidskr; 1964 May; 68():345-51 CONCL. PubMed ID: 14146538 [No Abstract] [Full Text] [Related]
20. Biodegradable drug delivery systems based on aliphatic polyesters: application to contraceptives and narcotic antagonists. Pitt CG; Marks TA; Schindler A NIDA Res Monogr; 1981; 28():232-53. PubMed ID: 6791007 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]